152 Re-irradiation for recurrent paediatric diffuse midline glioma: an international, multi-institutional retrospective study

Clicks: 15
ID: 326711
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #253 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Children with recurrent diffuse midline gliomas (DMG) have limited therapeutic options at recurrence. Re-irradiation (RT2) may be used at progression but with uncertainty about benefit. Method We conducted a multi-institutional retrospective study of children aged <18 with DMG treated at three centres (Toronto, Canada; Birmingham, UK; Nottingham, UK). Patients with radiologic progression after first radiation (RT1) were included. Overall survival (OS) was calculated from the date of progression after RT1. Survival was analysed using Kaplan–Meier and log-rank test. Multivariable Cox regression identified independent predictors of OS. Results 167 patients were included with median age 7.9 years; 54 (32%) received RT2. Children selected for RT2 had longer interval from RT1 to progression (9.5 vs 5.9 months, p < 0.0001). Median OS from progression was longer in the RT2 group (7.1 months) compared to the no RT2 cohort (2.5 months; p < 0.0001). Six-month OS was 68% vs 16% and 1-year OS was 19% vs 3%, respectively. Patients needing RT2 ≥1 year after RT1 had superior survival compared with earlier RT2 (9.7 vs 5.0 months; p = 0.0041). Higher RT2 dose (≥30.6 Gy) showed a non-significant trend towards longer OS (p = 0.086). In multivariable analysis, use of RT2 was the strongest independent predictor of survival (HR 0.29, 95% CI 0.20–0.42; p < 0.0001). Older age at RT1 and clinical trial enrolment were also associated with improved survival. Conclusions In this large, multi-institutional international cohort, children with DMG treated with re-irradiation at progression showed a survival benefit, supporting re-irradiation as a key component of salvage therapy.
Reference Key
openalex_W7204450450 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ajay Thomas Alex, Sean Hasson, Helen Benghiat, Liam Herbert, Claire Esler, Louise Brookes, Molly Bamber, Derek Tsang
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.043
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.043/70805931/noag172.043.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.